Dermatology Xagena
The results of a phase I study in advanced melanoma suggested complementary clinical activity with Nivolumab ( Opdivo ), a PD-1 checkpoint inhibitor, plus Ipilimumab ( Yervoy ), a CTLA-4 checkpoint in ...
New six-and-a-half-year data from CheckMate -067, a randomized, double-blind, phase 3 clinical trial, demonstrating durable improvement in survival with first-line Nivolumab ( Opdivo ) plus Ipilimumab ...
